Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO).

Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO).

Dose escalation may improve curability in intermediate-risk prostate carcinoma. A multicenter national program was developed to assess toxicity and tumor response with hypofractionated stereotactic boost after conventional radiotherapy in intermediate-risk prostate cancer.Between August 2010 and Apr...

Full description

Bibliographic Details
Main Authors: David Pasquier, Philippe Nickers, Didier Peiffert, Philippe Maingon, Pascal Pommier, Thomas Lacornerie, Geoffrey Martinage, Emmanuelle Tresch, Eric Lartigau
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5708754?pdf=render

Internet

http://europepmc.org/articles/PMC5708754?pdf=render

Similar Items